Elevian

Overview
News
Longevity Tech?
Product stageSegments
Seed
?
Drug discovery and repurposing
?

Elevian develops medicines that restore regenerative capacity, with the potential to treat and prevent many age-related diseases. The company researches the tissue and organic regeneration capabilities acquired by older animals after being transfused with the blood of young animals and develops drugs to restore regenerative capacity in humans, with the potential to halt and treat a range of aging-related diseases.

Elevian’s programs in the pipeline utilize recombinant growth differentiation factor 11 (rGDF11) and other modulators of the GDF11 pathway. These are targeted at neurologic diseases and strokes, where the focus is to prevent patients from becoming permanently disabled or dying post-stroke. These programs are in preclinical stages as of October 2023.  

GDF11 is a circulating blood factor that is claimed to stimulate regeneration broadly and consistently in multiple tissues and organs. rGDF11 is claimed to promote neovascularization (new blood vessel formation), stimulate neurogenesis (new neuron formation), and reduce inflammation. The effects of rGDF11 seem to be independent of the type of injury (clots vs. bleeds). In addition, it is claimed that rGDF11 can promote recovery and regeneration in several preclinical models of aging-related diseases, including cardiovascular, neurological, metabolic, pulmonary, renal, inflammatory, and skeletal muscle dysfunction.

Elevian holds exclusive worldwide rights to a portfolio of patents from Elevian, Harvard, and affiliated research partners. These include the patents for the pharmaceutical composition comprising a GDF11 polypeptide, the use of GDF11 to treat stroke, obesity, type II diabetes, and a number of aging-related diseases, and new compositions to modulate GDF11 activity.

Funds and financials

As of November 2023, the company’s latest funding round was in September 2021, where the company raised USD 40 million in Series A funding led by Prime Movers Lab. The funds were intended to be used to submit an investigational new drug application, scale manufacturing, and complete Phase I clinical trials for its lead indication of stroke recovery.

HQ location:
Pagliuca Harvard Life Lab 127 Western Ave Allston MA USA
Founded year:
2017
Employees:
11-50
IPO status:
Private
Total funding:
USD 64.3 mn
Last Funding:
USD 40.0 mn (Series A; Sep 2021)
Last valuation:
-
Key competitors
Filter by the segments to which the disruptor belongs
All Segmentsexpand
 
Loading...
Loading...
Loading...
Loading...
Product Overview
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Product Metrics
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Company profile
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Funding data are powered by Crunchbase
arrow
menuarrow
Click here to learn more
Get a demo

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.